Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
Year: 2020
Type: article
Abstract: Comparison of long-term outcomes in patients with refractory/relapsed grade 1-2 follicular lymphoma (FL) after allogeneic (allo-HCT) vs. autologous hematopoietic cell transplantation (auto-HCT) in the rituximab-era.
DOI: 10.17615/pp4y-0s62
Authors: Bachanova, Veronika, Carreras, Jeanette, Klein, Andreas, Ganguly, Siddhartha, Hamadani, Mehdi, Wood, William A., Usmani, Saad Z., D'Souza, Anita, Kröger, Nicolaus M., Gale, Robert Peter, Hertzberg, Mark S., Bashey, Asad, Mussetti, Alberto, Maloney, David G., Bacher, Ulrike, Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Ahn, Kwang Woo, Cohen, Jonathon B., Smith, Sonali M., Hari, Parameswaran N., Laport, Ginna G., Holmberg, Leona A., Sureda, Anna M., Vij, Ravi, Ku, Grace H., Miller, Alan M., Klyuchnikov, Evgeny, Freytes, César O., Olsson, Richard F., Slavin, Shimon
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: U.S. Department of Defense, U.S. Department of Health and Human Services, Amgen, GlaxoSmithKline, Sanofi, WellPoint, Health Research, Teva Pharmaceutical Industries, Ariad Pharmaceuticals, Celgene, HistoGenetics, Osiris Therapeutics, Tarix Pharmaceuticals, Therakos, University of Minnesota, Blue Cross and Blue Shield Association, StemCyte, Medical College of Wisconsin, Otsuka America Pharmaceutical, Sigma-Tau Pharmaceuticals, Actinium Pharmaceuticals, Chimerix, Incyte, Otsuka America, Kiadis Pharma, Swedish Orphan Biovitrum, Medac, Health Resources and Services Administration, Genentech, Onyx Pharmaceuticals, U.S. Navy, Allos Therapeutics, Takeda Oncology, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases
Awards: G1384772222, G1515501300, G1769371581, G205138692, G2108949772, G2220088171, G2814340220, G317906537, G3231857129, G4298420724, G4930744573, G5569911400, DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE, G7160503914, G8122066879, G8872364087, G8876996369, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research
OpenAlex ID: W4298840771